This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Dyslipidemia	Diacylglycerol O-acyltransferase-1 (DGAT1)	Rodent and cell culture studies suggest the DGAT1 inhibitor ABT-046 could help treat dyslipidemia. In a human cell line, ABT-046 inhibited triglyceride formation with an IC_{50} of 78 nM. In mice receiving a lipid challenge, oral ABT-046 lowered serum triglycerides compared with vehicle ($p < 0.05$). Next steps could include testing ABT-046 in animal models of diabetes. ABT-046 is in preclinical development at Abbott Laboratories for undisclosed indications. Novartis AG's DGAT1 inhibitor, LCQ908, is in Phase II testing in diabetes.	Patent application filed; available for licensing	Souers, A.J. <i>J. Med. Chem.</i> ; published online Jan. 20, 2012; doi:10.1021/jm201524g Contact: Andrew James Souers, Abbott Laboratories, Abbott Park, Ill. e-mail: andrew.souers@abbott.com
<i>SciBX</i> 5(6); doi:10.1038/scibx.2012.155 Published online Feb. 9, 2012				